Divi's Laboratories Limited (DIVISLAB) Net Income 2023–2026

Name: Divi's Laboratories Limited (DIVISLAB) net income history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Divi's Laboratories Limited annual net income for fiscal 2026 was ₹25.7 billion, an increase of 17.2% from ₹21.9 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

DIVISLAB Annual Net Income

Net Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Net Income	₹25.7B	₹21.9B	₹16.0B	₹18.2B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DIVISLAB Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Net Income	₹9.0B	₹7.5B	₹5.8B	₹5.5B	₹6.6B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

4502 Net Income — Takeda Pharmaceutical Company Limited
SUNPHARMA Net Income — Sun Pharmaceutical Industries Limited
4507 Net Income — Shionogi & Co., Ltd.
TORNTPHARM Net Income — Torrent Pharmaceuticals Limited
4523 Net Income — Eisai Co., Ltd.
4151 Net Income — Kyowa Kirin Co., Ltd.

More DIVISLAB metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All DIVISLAB financial statements → Interactive DIVISLAB charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.